The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Protecting the Frontline in Biodefense Research: The Special Immunizations Program
epidemiology of dengue hemorrhagic fever, and on emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters.
Dr. Burke’s career-long mission has been prevention and mitigation of the impact of epidemic infectious diseases of global importance. His research activities have spanned a wide range of science “from the bench to the bush,” including development of new diagnostics, population-based field studies, clinical vaccine trials, computational modeling of epidemic control strategies, and policy development and evaluation.
W. Emmett Barkley, Ph.D., is the president of Proven Practices, LLC where he supports environmental health and safety programs at major academic research universities and government agencies. He is the former director of laboratory safety at the Howard Hughes Medical Institute and has recently served on the Committee on Prudent Practices in the Laboratory: An Update. His experience includes 24 years at the National Institutes of Health (NIH), where he served as the founding director of the NIH Division of Safety. Dr. Barkley was a principal contributor to several authoritative guidelines in the fields of biological and chemical safety, including the NIH Guidelines for the Laboratory Use ofChemical Carcinogens, the NIH Guidelines for Research Involving RecombinantDNA Molecules, and the CDC/NIH publication Biosafety in Microbiologicaland Biomedical Laboratories. He received a bachelor of civil engineering from the University of Virginia and the master of science and doctorate degrees in environmental health from the University of Minnesota.
Gerardo Chowell, Ph.D., is an assistant professor in the School of Human Evolution and Social Change at Arizona State University (ASU). Prior to joining ASU, Dr. Chowell was a director’s postdoctoral fellow with the Mathematical Modeling and Analysis Group (Theoretical Division) at the Los Alamos National Laboratory. He performs mathematical modeling of emergent and re-emergent infectious diseases (including SARS, influenza, Ebola, and foot-and-mouth disease) with an emphasis in quantifying the effects of public health interventions. His research interests include agent-based modeling, model validation, and social network analysis. Dr. Chowell received his Ph.D. in biometry from Cornell University and his engineering degree in telematics from the Universidad de Colima, Mexico.
Alan S. Cross, M.D., is professor of medicine at the University of Maryland School of Medicine and researcher at its Center for Vaccine Development. Dr. Cross has three major areas of interest: the development of a vaccine for the prevention and treatment of sepsis, the early interactions of Bacillus anthracis with the host immune system, and the role of sialic acid in innate and adaptive immunity. A previous phase I study with a detoxified endotoxin vaccine complexed to group B meningococcal outer membrane protein revealed that while